Gsa Capital Partners LLP 2seventy Bio, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 114,073 shares of TSVT stock, worth $564,661. This represents 0.02% of its overall portfolio holdings.
Number of Shares
114,073
Previous 13,479
746.3%
Holding current value
$564,661
Previous $64,000
423.44%
% of portfolio
0.02%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TSVT
# of Institutions
126Shares Held
44.5MCall Options Held
17.3KPut Options Held
2.9K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$29.5 Million1.11% of portfolio
-
Goldman Sachs Group Inc New York, NY4.29MShares$21.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$18.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$18.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.92MShares$14.4 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $187M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...